Humana, DrFirst Ties Up to Boost Statin Use in High-Risk Patients

16.08.25 04:00 Uhr

Werte in diesem Artikel
Aktien

234,90 EUR 16,00 EUR 7,31%

Indizes

6.731,1 PKT 15,8 PKT 0,23%

Humana Inc. HUM recently partnered with health technology innovator DrFirst to unveil a program aimed at closing care gaps for patients grappling with chronic conditions such as diabetes and cardiovascular disease. The first stage of this initiative focuses on boosting statin therapy usage among eligible patients. Because statin therapy in certain Medicare patients is linked to lower cardiovascular risk, improved outcomes and reduced costs, Humana is leveraging DrFirst’s prescription orchestration platform to engage prescribers directly within their clinical workflow. This allows Humana to send statin therapy recommendations for high-risk patients straight to providers. With a single click, providers can approve the suggestion and issue a new prescription or indicate why it may not be suitable for the patient.DrFirst’s platform turns fragmented workflows into real-time clinical collaboration. This rules-based system enables seamless interoperability among providers, pharmacies and payers, ensuring critical patient information is shared quickly to improve care. Humana seems prudent in selecting DrFirst, which has supported healthcare providers and patients through advanced medication management solutions for nearly three decades now. More than 350,000 prescribers, 71,000 pharmacies, 300 EHR and HIS systems, and more than 2,000 hospitals in the US and Canada use DrFirst technology to enhance workflows, improve secure communication and drive better health results.Benefits of the Recent Move to HumanaThe recent initiative reflects Humana’s sincere efforts to strengthen its longstanding ties with DrFirst. In 2015, they jointly introduced the first real-time prescription benefit tool, giving providers the ability to access patient-specific coverage details, medication costs and prior authorization requirements right at the point of prescribing.Also, the beneficial nature of the DrFirst platform usage in the form of better health outcomes is likely to retain existing customers and attract new ones toward opting for Humana’s health care plans. Increased plan adoption is expected to expand HUM’s membership base and bring higher premium revenues to the health insurer. Premiums advanced 8.6% year over year in the first half of 2025 and total medical membership came in at 14.8 million as of June 30, 2025. Similar to Humana, other health insurers such as UnitedHealth Group Incorporated UNH, Centene Corporation CNC and Molina Healthcare, Inc. MOH boast a strong membership base and benefit from higher premiums.Through the UnitedHealthcare unit, UNH devises effective Medicare and Medicaid businesses as well as integrates lucrative features from time to time. These affordable plans expand the membership base and fetch growing premiums. The UnitedHealthcare business catered to 50.1 million people as of June 30, 2025, which grew 2.1% year over year. Premiums rose 12.6% year over year in the first half of 2025.Centene’s revenue growth is underpinned by a strong membership base in its Medicaid, Medicare and Commercial Marketplace business. As of June 30, 2025, Centene’s total membership reached 28 million. Its Commercial Marketplace division exhibited strength, serving 5.9 million members as of June 30, 2025, an impressive 33.2% increase year over year. In the first half of 2025, premium and service revenues rose 17.5% compared with the prior year. Molina Healthcare's premium revenues have experienced significant growth, fueled by the strong performance of its Medicaid and Medicare businesses. In the first half of 2025, premium revenues increased 13.4% year over year. Management anticipates 2025 premium revenues to be $42 billion. As of June 30, 2025, total membership grew 3% year over year. See our %%CTA_TEXT%% report – free today!7 Best Stocks for the Next 30 DaysWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Humana und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Humana

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Humana

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Humana Inc.

Wer­bung

Analysen zu Humana Inc.

DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
09.11.2017Humana Sector PerformRBC Capital Markets
20.10.2017Humana OutperformBMO Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
20.10.2017Humana OutperformBMO Capital Markets
24.01.2017Humana HoldStifel, Nicolaus & Co., Inc.
05.05.2016Humana BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
09.11.2017Humana Sector PerformRBC Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
07.12.2016Humana HoldCantor Fitzgerald
13.10.2016Humana Sector PerformRBC Capital Markets
22.07.2016Humana Mkt PerformFBR Capital
DatumRatingAnalyst
14.03.2008Humana neues KurszielLehman Brothers Inc.
03.02.2006Update Humana Inc.: UnderperformCredit Suisse First Boston
26.01.2006Update Humana Inc.: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Humana Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen